Oragenics, Inc. (NYSE:OGEN - Get Free Report)'s share price traded down 4.6% during mid-day trading on Thursday . The company traded as low as $3.34 and last traded at $3.53. 209,517 shares changed hands during mid-day trading, an increase of 105% from the average session volume of 102,268 shares. The stock had previously closed at $3.70.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen started coverage on shares of Oragenics in a research report on Thursday, May 15th. They set a "sell" rating on the stock.
View Our Latest Stock Report on OGEN
Oragenics Stock Down 4.6%
The stock has a market cap of $75.81 million, a PE ratio of -0.50 and a beta of 0.94. The stock's fifty day moving average price is $5.43 and its 200 day moving average price is $7.89.
About Oragenics
(
Get Free Report)
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oragenics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oragenics wasn't on the list.
While Oragenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.